SpeeDx Ciprofloxacin gyrA Assay for N. Gonorrhoeae Gonococcal Infection

Recruiting now · Not applicable

Conditions studied: Neisseria Gonorrhoeae Infection

In brief

This study aims to test the effectiveness of using of SpeeDx Resistance Plus assay to guide treatment of Neisseria gonorrhoeae (Ng) in a sexual health clinic setting.

Key facts

Study ID

NCT05286931

Run by

University of Washington

People needed

1800

Starts

2022-03-03

Expected to finish

2026-12-31

Last updated by the study team

2022-03-18

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: accepted.

You may qualify if…

• English speaking
• Have access to the internet (via computer or phone) on at least a weekly basis
• Asymptomatic (as defined below)

You may not qualify if…

• Urogenital symptoms consistent with a sexual transmitted infection (other than vaginitis associated with trichomonas vaginalis, bacterial vaginosis or yeast). Symptoms consistent with cervicitis, urethritis, or PID will not be offered enrollment.
• Antibiotic use within the last 2 weeks
• Contact to syphilis
• Contact to an STI and are unwilling to defer empiric treatment until diagnostic test results return
• Anyone receiving a gonococcal-active drug (such as Doxycycline, Penicillin, Ceftriaxone) during the visit. Those receiving metronidazole, fluconazole, or clotrimazole will not be excluded.
• Known allergy to ciprofloxacin and/or ceftriaxone

Where it is running

• Public Health -- Seattle & King County Sexual Health Clinic — Seattle, Washington, United States (enrolling)

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.